PU-H71 for Lymphoma

Phase-Based Progress Estimates
Lymphoma+4 More
PU-H71 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, called PU-H71, to find out what effects it has on patients and cancer cells. PU-H71 blocks a protein called Heat Shock Protein-90 (Hsp90). Hsp90 is found in both normal and cancer cells, but may be more important in cancer cells. Attacking Hsp90 can stop the function of certain proteins that are needed for cancer cells to survive.

Eligible Conditions
  • Lymphoma
  • Myeloproliferative Neoplasms (MPNs)
  • Solid Metastatic Tumor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Lymphoma

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: 2 years

2 years
To assess anti-tumor activity as defined by response rate
To assess the safety of PU-H71 in patients with advanced malignancies.
To assess the tolerability of PU-H71 in patients with advanced malignancies.
To determine the maximum tolerated dose (MTD) based on toxicity analysis.
To evaluate 124I-PU-H71 as a non-invasive means to determine tumor pharmacokinetics and intra-tumoral concentration
Hour 48
To assess the pharmacokinetics of PU-H71 in patients with advanced malignancies.

Trial Safety

Safety Progress

1 of 3

Other trials for Lymphoma

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

47 Total Participants · 1 Treatment Group

Primary Treatment: PU-H71 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: PU-H71 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,300 Total Patients Enrolled
148 Trials studying Lymphoma
7,765 Patients Enrolled for Lymphoma
Komal Jhaveri, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
28 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a serum bilirubin level of at least 1.5 mg/dL.
You have a serum creatinine level of ≤ 1.
You have a performance status of 0, 1, or 2.
You have a neutrophil count ≥ 1,000/μL, platelet count ≥ 50,000/μL, and hemoglobin ≥ 8 g/dL.
The safety-expansion phase will be open to accrual only for patients with MPN.
Patients with solid malignancies and lymphoma, radiographically detectable (Either FDG-PET, CT scan/ MRI or Bone Scan) or measurable disease will be required.
You have had prior therapy for advanced malignancy with no current curative option.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.